South Australian Neonatal Medication Guidelines

Indometacin
1mg injection

© Department for Health and Ageing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms
Indometacin

Dose and Indications

Treatment of significant patent ductus arteriosus (PDA)

Intravenous

<table>
<thead>
<tr>
<th>Age at 1st Dose</th>
<th>1st Dose</th>
<th>2nd dose</th>
<th>3rd dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(To be administered 12 - 24 hours after first dose)</td>
<td>(To be administered 12 - 24 hours after second dose)</td>
</tr>
<tr>
<td>&lt; 48 hours</td>
<td>0.2mg/kg</td>
<td>0.1mg/kg</td>
<td>0.1mg/kg</td>
</tr>
<tr>
<td>&gt; 48 hours</td>
<td>0.2mg/kg</td>
<td>0.2mg/kg</td>
<td>0.2mg/kg</td>
</tr>
</tbody>
</table>

If the ductus arteriosus does not close 48 hours after the last dose or if it re-opens, a second course, as above may be given.

PLEASE NOTE: Babies less than 1kg may require a dose less than 0.1mg. Please ensure you double check the dose calculation.
Preparation and Administration

**Intravenous**

Add 2mL of water for injection to the vial (1mg) and shake gently to dissolve. The resulting solution contains 0.5mg/mL indometacin.

Example calculations:

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.05mg</th>
<th>0.1mg</th>
<th>0.2mg</th>
<th>0.3mg</th>
<th>0.4mg</th>
<th>0.5mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.2mL</td>
<td>0.4mL</td>
<td>0.6mL</td>
<td>0.8mL</td>
<td>1mL</td>
</tr>
</tbody>
</table>

Administer as an intravenous infusion over 20 to 30 minutes.

**Compatible Fluids**

Water for Injection, Sodium chloride 0.9%

Further dilution is not recommended. Indometacin Agila is not buffered and reconstitution with solutions at pH values below 6 may result in precipitation of the insoluble indometacin free acid moiety. It cannot be run with parenteral nutrition solutions as they usually have a pH between 4-5.

**Adverse Effects**

**Common**

Gastrointestinal perforation (particularly if used concurrently or in close proximity to corticosteroids), bleeding, salt and fluid retention, hypertension

**Infrequent**

Hyperkalaemia, renal impairment, rash

**Rare**

Blood dyscrasias, interstitial nephritis, acute renal failure, hepatitis

**Monitoring**

- Assess for ductal closure
- Renal function and urine output
- Serum electrolytes, Blood Urea Nitrogen (BUN) and glucose
- Assess for signs of bleeding
Practice Points

> Slow administration is essential to prevent reduction to organ blood flow
> If anuria or oliguria occurs after any dose, further dosing should be reviewed
> Indometacin is contraindicated in babies with active bleeding, severe thrombocytopenia and bleeding disorders, known or suspected NEC, congenital heart disease with ductal-dependant systemic blood flow or renal failure
> Indometacin solution should be prepared only with 2 ml of preservative free sterile sodium chloride injection or water for injection. Preparations containing glucose must not be used.
> Use with caution in known infection
> Indometacin may decrease clearance of aminoglycosides. Hence strict surveillance of aminoglycoside serum levels is recommended in those babies who have both indometacin and aminoglycosides prescribed
> Before administration of indometacin, an echocardiographic examination should generally be performed in order to detect a haemodynamically significant patent ductus arteriosus and to exclude pulmonary hypertension and duct-dependent congenital heart disease

References

Indometacin
1mg injection

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 24/04/2023
PDS reference: CG198
Policy history:
Is this a new policy (V1)? N
Does this policy amend or update and existing policy? Y
If so, which version? V1
Does this policy replace another policy with a different title? Y
If so, which policy (title)? Indometacin

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>24/04/2018</td>
<td>V2</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed in line with 5 year scheduled timeline for review.</td>
</tr>
<tr>
<td>25/2/15</td>
<td>V1</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Original SA Health Safety and Quality Strategic Governance Committee approved version.</td>
</tr>
</tbody>
</table>